People · Operator
Named in public records as an officer, director or promoter · active 2006–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2017 |
| SARcode Corp | — | Biotechnology | Series C | $99.6M | $1.8B | 2006 |
| Progentos Therapeutics, Inc. | — | Pharma | Series C | $68.6M | $634.3M | 2024 |
| Prolacta Bioscience Inc | — | Biotechnology | Series B | $64.7M | $353.6M | 2016 |
Dan Janney at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dan Janney on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Alexander | 2 | 6 |
| Frank Foster | 1 | 12 |
| John McKearn | 1 | 6 |
| Peter Moldt | 1 | 6 |
| John Shields | 1 | 6 |
| DENNIS HENNER | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Emmett Cunningham | 1 | 4 |
| Paul Walker | 1 | 4 |
| David Brailer | 1 | 4 |
| David Dreyer | 1 | 3 |
| Thomas Gadek | 1 | 3 |
| Ned Brown | 1 | 3 |
| Quinton Oswald | 1 | 3 |
| Garheng A. Kong | 1 | 2 |
| Frank D. Foster | 1 | 2 |
| Cassidy Blundell | 1 | 2 |
| Nenad Tomasevic | 1 | 2 |
| Martin Sutter | 1 | 2 |
| Victoria Niklas | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.